Pfizer COVID Pill Helped High-Risk Seniors But Showed No Benefit in Younger Adults: Study
Headline from NBC 6 South Florida
The findings reflect the changing nature of the pandemic, in which the vast majority of people already have some protection against the virus due to vaccination or prior infection
NBC 6 South Florida's own description from its feed. We collect headlines and these descriptions, not full articles; read the original reporting below.
Pfizer’s COVID-19 pill appears to provide little or no benefit for younger adults. That's according to a large study by Israeli researchers. The study of more than 100,000 patients showed
The findings reflect the changing nature of the pandemic, in which the vast majority of people already have some protection against the virus due to vaccination or prior infection
Results from 109,000-patient study show drug still reduces risk of hospitalization, death for high-risk seniors, raises questions on use in US, where it has become a go-to treatment
Pfizer's COVID-19 pill appears to provide little or no benefit for younger adults, while still reducing the risk of hospitalization and death for high-risk seniors, according to a large study published Wednesday.
